An observational study in Oropharyngeal Carcinoma, sponsored by M.D. Anderson Cancer Center. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-16.
Sponsored by M.D. Anderson Cancer Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Oropharyngeal Neoplasms by M.D. Anderson Cancer Center — 4 open to participants now, 10 under way, 1 of them phase 3. Oropharyngeal Neoplasms · M.D. Anderson Cancer Center.
Among the 26 studies in Oropharyngeal Neoplasms by M.D. Anderson Cancer Center, this one is the only one that started in 2021, is one of 9 observational ones, and was the 22nd registered.
370 studies on the registry are indexed under Oropharyngeal Neoplasms; 104 are open to participants now.
Browse Oropharyngeal Neoplasms studies →4 of the 26 studies in Oropharyngeal Neoplasms by M.D. Anderson Cancer Center are open now, in 1 country. Recruiting first, the newest first:
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 89 Oropharyngeal Neoplasms studies recruiting now, 76 (85%) set no upper age limit and 5 (6%) stop at 75 or younger; none take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 2
First in 2002; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 77 is below the median of 142 across 75 observational studies indexed under Oropharyngeal Neoplasms.
Median enrollment 25 across the 17 interventional studies, 370 across the 9 observational. Of the 8 that completed or were terminated, 5 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
M.D. Anderson Cancer Center is the lead sponsor of 3,051 studies on the registry; 580 are open to participants now.
Of its 614 completed or terminated interventional studies of FDA-regulated products, 409 (67%) have results posted.
7 of the studies in Oropharyngeal Neoplasms by M.D. Anderson Cancer Center that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01266044Phase 3M.D. Anderson Cancer CenterControlled Trial Of Acupuncture To Prevent Radiation-Induced Xerostomia | 2026-12-31 |
| NCT00498875M.D. Anderson Cancer CenterDepression and Adherence in Head and Neck Cancer | 2026-12-31 |
| NCT03224000M.D. Anderson Cancer CenterTrial of Magnetic Resonance Imaging Guided Radiotherapy Dose Adaptation in Human Papilloma Virus Positive Oropharyngeal Cancer | 2026-12-31 |
| NCT04874493M.D. Anderson Cancer CenterPatient Reported Outcome Post Radiation Therapy or Chemoradiotherapy Patient Care in Patients With Oropharyngeal Cancer | 2027-02-02 |
| NCT02253238M.D. Anderson Cancer CenterSensor-Assisted Prevention of Dehydration in Head and Neck Cancer Patients | 2027-04-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 26 studies in Oropharyngeal Neoplasms by M.D. Anderson Cancer Center, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study examines patient reported outcomes post radiation therapy or chemoradiotherapy patient care in patients with oropharyngeal cancer. This study may help researchers learn about the symptoms that patients with oropharyngeal cancer have after completing radiation therapy.
PRIMARY OBJECTIVE:
I. To provide evidence of clinically relevant symptoms for integrating into a user-friendly, automated pathway for real-time tracking and management of symptoms during post radiation therapy (RT)/chemoradiation (CRT) for oropharyngeal cancer (OPC).
OUTLINE:
Patients complete questionnaire over 10-20 minutes at baseline, 2 times every week during weeks 1-8 of radiation therapy, and at the end of the study.
Patients with OPC who were seen for new patient evaluation at clinics and head and neck cancer (HNC) centers at MD Anderson Cancer Center
Inclusion Criteria:
Patients complete questionnaire over 10-20 minutes at baseline, 2 times every week during weeks 1-8 of radiation therapy, and at the end of the study.
Other: Electronic Health Record Review · Other: Questionnaire Administration
Review of medical records
Complete questionnaire
Scores of symptoms on the MD Anderson Symptom Inventory - Head and Neck (MDASI-HN) relevant to toxicities
All symptom PRO items on MDASI-HN (MD Anderson Symptom Inventory - Head and Neck (MDASI) would be rated by patients on 0 -10 of severity scale, with 0 being no symptom, and 10 being symptom as bas as imagine.
Time frame: From the end of radiation therapy (RT)/chemoradiotherapy (CRT) treatment to 2 months post-treatment
Started Mar 2021 (actual). Primary completion is estimated for Feb 2027, 70 months after the start.
Of 47 observational studies under Oropharyngeal Neoplasms, half reached primary completion within 110 months of starting (the median), counting those still running; a quarter within 40. This study's planned 70 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.